Per clinical guidelines, patients with Type 2 diabetes and certain co-morbidities should initiate modern glucose-controlling therapies that also reduce the risk of cardiovascular and renal adverse events, such as GLP-1 RA and SGLT2i medications. But many indicated patients have not initiated these therapies, in part because some primary care doctors are uncomfortable with the complex […]
Read More